Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category.
美國銀行證券公司已提升Inspire醫療系統公司的評級（紐交所：INSP），並表示該公司現在屬於盈利增長類別。
Inspire Medical is expected to give its 2025 revenue guidance in early January, likely alongside its fourth-quarter results.
Inspire醫療預計將在1月初提供2025年的營業收入指引，可能與其第四季度業績一起發佈。
The company has already stated that it is comfortable with the Street's consensus of $950 million in revenue for 2025.
該公司已經表示，它對市場達成共識的2025年營業收入爲95000萬感到滿意。
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.
對於2024年，該公司預計銷售額將在79300萬至79800萬之間，而之前的指引爲78800萬至79800萬，市場共識爲79609萬。
BofA has upgraded the stock from Neutral to Buy with a price target of $255, up from $220.
美國銀行已將此股票的評級從中立上調至買入，目標價格從220美元上調至255美元。
Inspire Medical's outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
Inspire醫療對2025年的展望基於招聘更多員工、開設新中心、增加直接面向消費者的廣告、擴大治療適應症和提升產能的計劃。
Also Read: FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious
另請閱讀：FDA將Inspire醫療的睡眠呼吸暫停神經刺激器召回標記爲最嚴重。
The Inspire V system, expected to make a bigger impact in the second half of 2025 after the Inspire IV to V transition, could make the procedure easier and more accessible to more doctors, including general surgeons, ENTs, and neurosurgeons.
Inspire V系統預計在2025年下半年更大影響力，將使手術對更多醫生（包括普通外科醫生、耳鼻喉科醫生和神經外科醫生）變得更簡單、更可及。
In August, the FDA approved the Inspire V therapy system, which includes the next-generation neurostimulator and the associated Bluetooth patient remote and physician programmer.
在八月，FDA批准了Inspire V治療系統，該系統包括下一代神經刺激器和相關的藍牙患者遙控器及醫生編程器。
The company targets a soft launch in late 2024 and a full launch in 2025
該公司計劃在2024年底進行軟啓動，並在2025年進行全面啓動。
One major advantage of Inspire V is that it simplifies the procedure by eliminating the need to place the sensing lead, which was a more complicated part of the process.
Inspire V的一個主要優勢是簡化了手術，因爲不需要放置傳感導線，這曾是過程中的一個更復雜的部分。
The analyst writes, "There are limited smid cap profitable growth stocks with a new product story in 2025 and INSP screens attractive as we look for top smid cap ideas in 2025. INSP seems on the path towards double digit margins which is when valuations tend to inflect and strategic interest increases."
分析師寫道：「在2025年，只有有限的中型市值盈利成長股票具有新的產品故事，而INSP作爲我們在2025年尋找的頂級中型市值創意顯得很有吸引力。INSP似乎正在朝着兩位數的利潤率邁進，而這通常會導致估值變化和戰略興趣增加。」
Price Action: INSP stock is up 4.90% at $184.67 at last check Wednesday.
價格動態：截至週三最後一次檢查，INSP股票上漲4.90%，報184.67美元。
Photo by Ground Picture on Shutterstock
來自Shutterstock的Ground Picture拍攝的照片
- What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
- 在拒絕達能修訂收購提議後，Lifeway股票有什麼變化？
譯文內容由第三人軟體翻譯。
